Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT ID: NCT02575963

Last Updated: 2023-07-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-10-31
• Study Completion Date: 2020-05-31

Brief Summary

The study is a multicenter, open label Phase I/II trial.

1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion)

2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac225 alone (Phase 2 portion)

Detailed Description

The study is a multicenter, open label Phase I/II trial. Phase I, dose-escalation: This portion of the overall study uses a 3+3 design to estimate the maximum tolerated dose (MTD). The starting dose level will be 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4 - 7 days after 1 cycle of LDAC (20 mg subQ every 12 h x 10 days administered for cytoreduction) and the second fraction administered 4-7 days after the first fraction. Subjects will then go on to receive up to 11 additional cycles of LDAC or until progression of disease. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.

Phase II, efficacy component. The study was designed as a 2- stage minimax design. Patients will be given two infusions of Lintuzumab-Ac225, 4-8 days apart (Day 5-Day 9), initially at the dose level determined to be the MTD in the Phase I portion. The second dose of Lintuzumab-Ac225 may be delayed up to 14 days after the first dose for clinical or scheduling reasons. Response will be initially assessed on or around days 28-42 after the final study drug administration. The primary endpoint (CR+CRp + CRi) will be determined on day 42. Best response will be evaluated from Day 1, Dose 1 until the end of the study.

Conditions

AML

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1 (Completed)

Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.

Experimental: Phase 2

Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225.

Group Type: EXPERIMENTAL

Cytarabine (Phase 1 only)

Intervention Type: DRUG

Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.

Lintuzumab-Ac225

Intervention Type: BIOLOGICAL

In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.

Furosemide (Phase 1 only)

Intervention Type: DRUG

40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.

Spironolactone

Intervention Type: DRUG

25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.

Interventions

Cytarabine (Phase 1 only)

Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.

Intervention Type: DRUG

Lintuzumab-Ac225

In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.

Intervention Type: BIOLOGICAL

Furosemide (Phase 1 only)

40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.

Intervention Type: DRUG

Spironolactone

25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.

Intervention Type: DRUG

Other Intervention Names

Low dose Ara-C; LDAC; HuM195-Ac225; Actimab-A; Lasix; Aldactone

Eligibility Criteria

Inclusion Criteria

1. Untreated AML, including patients with an antecedent hematologic disorder or secondary disease. Patients with prior MDS may have received therapy with immunomodulatory agents or hypomethylating agents for this diagnosis. Patients with other prior cancer diagnoses are allowed as long as they have no measurable disease, are not undergoing active therapy, and have a life expectancy of ≥ 4 months.

2. Patients age ≥60 years who:

1. Are unwilling to receive intensive (e.g. 7+3) chemotherapy, or

2. Have poor-risk prognostic factors defined as antecedent hematologic disorder, prior chemotherapy or XRT, abnormal karyotype other than t(8;21), inv16, or t(16;16), any karyotype with FLT3-ITD, or presenting WBC>100K, or

3. Have significant comorbidities, that in the judgment of the investigator makes the subject unsuitable for standard dose induction chemotherapy (e.g. anthracycline and infusional cytarabine given as 7+3), or;

4. Any patient age ≥ 70 years.

3. Blast count ≥20%

4. Greater than 25% of blasts must be CD33 positive.

5. Adequate renal and hepatic function

6. ECOG ≤ 3

1. Untreated AML, including patients with an antecedent hematologic disorder or secondary disease. Patients with prior MDS may have received therapy with immunomodulatory agents for this diagnosis.

2. Patients age ≥60 years who:

1. Patients ≥60 years unfit to receive intensive (e.g., 7+3) chemotherapy who have:

• Congestive heart failure or documented cardiomyopathy with an EF ≤50%, provided that EF ≥35% or,
• Documented pulmonary disease with DLCO ≤65% or FEV1 ≤65%, provided that patients do not require more than 2 L of oxygen per minute or,
• Documented liver disease with marked elevation of transaminases >3 x ULN or,
• Serum creatinine >1.2 mg/dL

2. Have significant comorbidities, that in the judgment of the investigator makes the subject unsuitable for standard dose induction chemotherapy (e.g., anthracycline and infusional cytarabine given as 7+3); or

3. Any patient age ≥ 75 years.

3. Blast count ≥ 20% (WHO criteria)

4. Greater than 25% of blasts must be CD33 positive.

5. Have a circulating blast count of less than 200/mm3 (control with hydroxyurea or similar agent is allowed);

6. Creatinine < 2.0 mg/dl

7. Estimated creatinine clearance ≥ 50ml/min

8. Bilirubin ≤ 2.0 mg/dl; AST and ALT < 5.0 times the ULN

9. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

Exclusion Criteria

1. Patients with acute promyelocytic leukemia

2. Treatment with chemotherapy or biologic therapy within 3 weeks, except for hydroxyurea, which must be discontinued prior to treatment on study

3. Treatment with radiation within 6 weeks

4. Active serious infections uncontrolled by antibiotics

5. Active malignancy within 2 years of entry, except previously treated non-melanoma skin cancer, carcinoma in situ or cervical intraepithelial neoplasia, and organ confined prostate cancer with no evidence of progressive disease based on PSA levels and are not on active therapy.

6. Clinically significant cardiac or pulmonary disease

7. Patients with liver cirrhosis

8. Active CNS leukemia. Patients with symptoms of CNS involvement, particularly those with M4 or M5 subtypes, should undergo lumbar puncture prior to treatment on study to exclude CNS disease. Symptoms include cranial neuropathies, other neurologic deficits, and headache.

9. Psychiatric disorder that would preclude study participation

• Minimum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Actinium Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Avinash Desai, MD

Role: STUDY_CHAIR

Actinium Pharmaceuticals Inc.

Locations

UCLA Medical Center, Division of Hematology/Oncology

Los Angeles, California, United States

University of Kentucky, Markey Cancer Center

Lexington, Kentucky, United States

University of Louisville, James Graham Brown Cancer Center

Louisville, Kentucky, United States

Ochsner Medical Center, The Gayle and Tom Benson Cancer Center

New Orleans, Louisiana, United States

Mayo Clinic

Rochester, Minnesota, United States

Weill Medical College of Cornell University

New York, New York, United States

Columbia University Medical, Herbert Irving Comprehensive Cancer Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Duke Cancer Center

Durham, North Carolina, United States

University of Pennsylvania, Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, United States

St. Francis Cancer Center

Greenville, South Carolina, United States

Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center

Dallas, Texas, United States

Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation

Seattle, Washington, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

West Virginia University, Mary Babb Randolph Cancer Center

Morgantown, West Virginia, United States

Medical College of Wisconsin Cancer Center

Milwaukee, Wisconsin, United States

VA Caribbean Healthcare System

San Juan, , Puerto Rico

Countries

United States; Puerto Rico

References

Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015 Jun;15(6):347-60. doi: 10.1038/nrc3925.

Reference Type: BACKGROUND

PMID: 25998714 (View on PubMed)

Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2014:e126-31. doi: 10.14694/EdBook_AM.2014.34.e126.

Reference Type: BACKGROUND

PMID: 24857092 (View on PubMed)

Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011 Oct;4(4):306-20. doi: 10.2174/1874471011104040306.

Reference Type: BACKGROUND

PMID: 22202153 (View on PubMed)

Nikitaki Z, Velalopoulou A, Zanni V, Tremi I, Havaki S, Kokkoris M, Gorgoulis VG, Koumenis C, Georgakilas AG. Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair. Expert Rev Mol Med. 2022 Mar 31;24:e15. doi: 10.1017/erm.2022.6.

Reference Type: DERIVED

PMID: 35357290 (View on PubMed)

Related Links

http://jnm.snmjournals.org/content/58/supplement_1/456.abstract?sid=5073e99e-45a1-42c7-8f12-4d438e4a98d9&utm_source=TrendMD&utm_medium=cpc&utm_campaign=J_Nucl_Med_TrendMD_1

Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia.

https://ash.confex.com/ash/2015/webprogramscheduler/Paper81957.html

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Other Identifiers

API-01

Identifier Type: -

Identifier Source: org_study_id

NCT01756677

Identifier Type: -

Identifier Source: nct_alias